FTC To Pfizer: More Information On Wyeth Please
This article was originally published in The Pink Sheet Daily
Executive Summary
The request was anticipated, Pfizer says, noting the company will work “quickly and cooperatively” to provide the information.
You may also be interested in...
Former FTC Economists Question TARP Funding Behind Pfizer-Wyeth Deal
In reviewing the proposed Pfizer-Wyeth merger, the Federal Trade Commission should take into account that the deal would indirectly be financed with government bail out money that banks could better spend elsewhere to stimulate the economy, two former FTC chief economists recommend
Antitrust Enforcement Under Obama: Pfizer-Wyeth Offers An Early Test
President Obama pledged to reinvigorate antitrust enforcement during his campaign for the Oval Office. Pfizer's proposed acquisition of Wyeth gives the administration an early opportunity to test that promise
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.